Compare Organon & Co. Common Stock (OGN) vs Ventas Inc. Common Stock (VTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Ventas Inc. Common Stock — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Ventas Inc. Common Stock trades at $85.53 (market cap $43.01B). The key difference: Ventas Inc. Common Stock is far larger — about 11.9× Organon & Co. Common Stock's market cap, and Ventas Inc. Common Stock pays the higher dividend (2.48%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Ventas Inc. Common Stock for 6 Days on average.
| OGN | VTR | |
|---|---|---|
Market Cap | $3.62B | $43.01B |
Volume | 2,892,999 | 4,035,460 |
Sector | Health | Real Estate |
52-Week High | $13.81 | $100.53 |
52-Week Low | $5.70 | $68.89 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $11.04B | $55.73B |
Dividend Yield | 0.58% | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Ventas (VTR) trades at $83.85, up 0.37% today, amid a bearish technical signal with resistance near $84. The REIT reported Q2 2026 EPS of $0.14, slightly missing expectations, but maintains strong revenue growth with 2026 guidance at $6.4B. Analyst sentiment is positive with a $99.14 consensus target, supported by demographic tailwinds in senior housing.
The outlook for VTR is cautiously optimistic, driven by aging population trends boosting demand for senior housing. Risks include high valuation multiples and negative cash flow from aggressive investing. Wall Street's buy ratings (56%) suggest confidence in long-term growth, but investors should monitor earnings consistency and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Ventas Inc. Common Stock
Ventas is a real estate investment trust focused on healthcare properties. Its portfolio includes senior housing, medical office buildings, and research-related facilities.
Read more on VTR →
